Eurand

Agreement signed for oncology molecule

Published in Oncology Business Week, May 16th, 2004

Eurand, a specialty pharmaceutical company, announced that it has signed a research agreement with the University of Urbino (Italy) Biotechnology Centre to evaluate a potential new anticancer compound derived from indol-3-carbinol, a natural substance present in cruciferous vegetables.

Under the terms of the agreement, Eurand and the University of Urbino will collaborate to develop and evaluate the efficacy of the orally administered compound in the treatment of a broad range of cancers. The University of Urbino, which discovered the compound, will be responsible for its synthesis and preclinical evaluation.

Eurand will be responsible for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry